Schriftzug
Quelle: - pixabay.com:
Google
PR Newswire  | 

PACIRA BIOSCIENCES SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Pacira BioSciences, Inc. - PCRX

PR Newswire

play Anhören
share Teilen
feedback Feedback
copy Kopieren
newsletter
font_big Schrift vergrößern
Pacira Biosciences Inc 24,18 $ Pacira Biosciences Inc Chart +0,83%
Zugehörige Wertpapiere:

NEW ORLEANS, Jan. 24, 2025 /PRNewswire/ -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until March 14, 2025 to file lead plaintiff applications in a securities class action lawsuit against Pacira BioSciences, Inc. (the "Company") (NasdaqGS: PCRX), if they purchased the Company's securities between August 2, 2023 and August 8, 2024, inclusive (the "Class Period"). This action is pending in the United States District Court for the District of New Jersey.

Get Help

Pacira investors should visit us at https://claimsfiler.com/cases/nasdaq-pcrx-1/ or call toll-free (844) 367-9658. Lawyers at Kahn Swick & Foti, LLC are available to discuss your legal options.

About the Lawsuit

Pacira and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.

On August 9, 2024, the Company released the results of its lawsuit against eVenus for patent infringement relating to its Exparel product, which accounts for approximately 80% of the Company's revenue, disclosing that the U.S. District Court for the District of New Jersey had "found that the company's U.S. Patent No. 11,033,495 is not valid," and, thus, eVenus was not infringing on anything. On this news, the price of Pacira's shares fell over 47%, from a closing price of $22.36 per share on August 8, 2024 to a low of $11.70 per share on August 9, 2024.

The case is Alvarez v. Pacira BioSciences, Inc., et al., No. 25-cv-00322.

About ClaimsFiler

ClaimsFiler has a single mission: to serve as the information source to help retail investors recover their share of billions of dollars from securities class action settlements. At ClaimsFiler.com, investors can: (1) register for free to gain access to information and settlement websites for various securities class action cases so they can timely submit their own claims; (2) upload their portfolio transactional data to be notified about relevant securities cases in which they may have a financial interest; and (3) submit inquiries to the Kahn Swick & Foti, LLC law firm for free case evaluations.

To learn more about ClaimsFiler, visit www.claimsfiler.com.

Cision View original content:https://www.prnewswire.com/news-releases/pacira-biosciences-shareholder-alert-claimsfiler-reminds-investors-with-losses-in-excess-of-100-000-of-lead-plaintiff-deadline-in-class-action-lawsuit-against-pacira-biosciences-inc---pcrx-302360006.html

SOURCE ClaimsFiler


Für dich aus unserer Redaktion zusammengestellt

Dein Kommentar zum Artikel im Forum

Jetzt anmelden und diskutieren Registrieren Login

Hinweis: ARIVA.DE veröffentlicht in dieser Rubrik Analysen, Kolumnen und Nachrichten aus verschiedenen Quellen. Die ARIVA.DE AG ist nicht verantwortlich für Inhalte, die erkennbar von Dritten in den „News“-Bereich dieser Webseite eingestellt worden sind, und macht sich diese nicht zu Eigen. Diese Inhalte sind insbesondere durch eine entsprechende „von“-Kennzeichnung unterhalb der Artikelüberschrift und/oder durch den Link „Um den vollständigen Artikel zu lesen, klicken Sie bitte hier.“ erkennbar; verantwortlich für diese Inhalte ist allein der genannte Dritte.


Weitere Artikel des Autors

Themen im Trend